首页> Journal for immunotherapy of cancer> Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA).

Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA).

导出 LinkOut

翻译打印收藏纠错

第一作者： Patrick,Danaher

第一单位： NanoString Technologies Inc Seattle WA USA pdanaher@nanostring.com.

作者： Patrick,Danaher ^[1] ; Sarah,Warren ^[2] ; Rongze,Lu ^[3] ; Josue,Samayoa ^[4] ; Amy,Sullivan ^[5] ; Irena,Pekker ^[6] ; Brett,Wallden ^[7] ; Francesco M,Marincola ^[8] ; Alessandra,Cesano ^[9]

作者单位： NanoString Technologies Inc Seattle WA USA pdanaher@nanostring.com. ^[1] NanoString Technologies Inc Seattle WA USA swarren@nanostring.com. ^[2] 0000 0004 0572 4227grid.431072.3AbbVie Inc. Redwood City CA USA Rongze.lu@abbvie.com. ^[3] 0000 0004 0572 4227grid.431072.3AbbVie Inc. Redwood City CA USA josue.samayoa@abbvie.com. ^[4] NanoString Technologies Inc Seattle WA USA asullivan@nanostring.com. ^[5] NanoString Technologies Inc Seattle WA USA ipekker@nanostring.com. ^[6] NanoString Technologies Inc Seattle WA USA bwallden@nanostring.com. ^[7] 0000 0004 0572 4227grid.431072.3AbbVie Inc. Redwood City CA USA francesco.marincola@abbvie.com. ^[8] NanoString Technologies Inc Seattle WA USA acesano@nanostring.com. ^[9]

关键词 Checkpoint inhibition Gene signature The Cancer Genome Atlas (TCGA)Tumor inflammation signature (TIS)